Discover
IPHA
Innate Pharma S.A.
1.90
1 x 1.88
1 x 1.94
bid
ask
-
0.01
0.52%
1 @ 04:00 PM
1.90 +0.00 (0.00%)
| Ytd | 8.57% | |
| 1y | -2.06% |
1.85
day range
1.93
1.17
52 week range
2.71
| Open | 1.92 | Prev Close | 1.91 | Low | 1.85 | High | 1.93 | Mkt Cap | 212.23M |
| Vol | 91.44K | Avg Vol | 149.71K | EPS | -0.59 | P/E | N/A | Forward P/E | 4.67 |
| Beta | 0.87 | Short Ratio | 5.63 | Inst. Own | 0.50% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 1.97 | 200-d Avg | 1.75 | 1yr Est | 7.41 |
IPHA News
seekingalpha.com
Innate Pharma S.A. (IPHA) Q2 2026 Earnings Call Transcript
Innate Pharma S.A. (IPHA) Q2 2026 Earnings Call Transcript
marketbeat.com
Innate Pharma Q2 Earnings Call Highlights
Innate Pharma NASDAQ: IPHA said its first-half 2026 developments included the closing of a strategic
benzinga.com
Innate Pharma H1 2026 Earnings Call Transcript
Innate Pharma (NASDAQ:IPHA) held its quarterly earnings conference call on Thursday. Below is the co
benzinga.com
Earnings Scheduled For September 17, 2026
Companies Reporting Before The Bell • 111 (NASDAQ:YI) is projected to report earnings for its second
benzinga.com
Innate Pharma H1 EPS $(0.24) Misses $(0.16) Estimate, Sales $6.583M Miss $9.100M Estimate
Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.24) per share which missed the analyst
businesswire.com
Innate Pharma Reports First Half 2026 Business Update and Financial Results
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris:
businesswire.com
Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: